Travere Therapeutics
TVTX
50 hedge funds and large institutions have $286M invested in Travere Therapeutics in 2014 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$35.2M |
| 2 |
Jennison Associates
New York
|
+$30.3M |
| 3 |
BC
Broadfin Capital
New York
|
+$24.7M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$21.7M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$17.7M |
Top Sellers
TVTX Hedge Fund Activity: Q1 2014 in Review
50 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2014, worth a combined $286M.
Buyers outnumbered sellers: 50 funds opened new TVTX positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was QVT Financial, opening a new position worth an estimated $35.2M.
- 50 institutional investors held Travere Therapeutics (TVTX) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $286M of Travere Therapeutics stock for Q1 2014.
- 50 funds opened new Travere Therapeutics positions in Q1 2014 and 0 closed out, a net change of +50 holders.
- The largest Travere Therapeutics buyer in Q1 2014 was QVT Financial, an estimated $35.2M added.
Based on aggregated 13F filings for Q1 2014.